SUMMARY Human synovial tissues have been assayed for the production of cartilage degrading activity (CDA). This activity is thought to be homologous with catabolin/interleukin 1 (ILl) produced by porcine synovium and leucocytes and by human leucocytes. The CDA of 26 rheumatoid (RA) and 41 non-rheumatoid synovia was measured on a dry weight basis. The rheumatoid synovia showed a threefold increase in activity over the non-rheumatoid, but there was no significant overall difference on a deoxyribonucleic acid (DNA) basis. The rheumatoid synovia appeared to consist of two populations; in over half the samples CDA was not related to cellularity, but eight patients had a high CDA and a high cellularity.
Using cocultivation of porcine cartilage and synovial tissue, Fell and Jubb showed that the degradation of the cartilage was not entirely explicable on the basis of diffusion of proteolytic enzymes from the synovial tissues. ' Dingle suggested that the breakdown of the cartilage might be caused by a diffusible factor secreted by the damaged synovial tissue.) A search for this factor, which was later named 'catabolin', led to the isolation3 and subsequent purification of catabolin.4 5 Catabolin acts on living chondrocytes to stimulate increased catabolic activity and to diminish the synthesis of proteoglycan and collagen. Its action is mediated by specific receptors on the chondrocyte surface; it does not have any action on dead cartilage since it has no hydrolytic activity for matrix molecules. Most of the work on the cartilage degrading activity of this factor has been carried out on the material obtained from porcine tissues, and relatively little research into the nature and properties of the human synovial analogue of porcine catabolin has been undertaken. This is largely due to the difficulties in obtaining human synovial membrane in sufficient quantities to attempt purification. Nevertheless there has been much speculation as to whether catabolin-like cartilage degrading activity The tissues were transferred immediately after surgery to Dulbecco's modified Eagle's minimal essential medium (DMEM). Within three hours Svnosial tissue was obtained at surger. The tissuc was cultured for two periods of 24 h in DMEM ait 37C. Saimplcs wsere dried and assaved for dry wscight aind DNA. Glueosc utilisation in the sN nos\ial culturcs Awas mcasured aIs dcscrihcd hs Brow n.'
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samples were dissected using full sterile precautions in a class II vertical flow cabinet to give pieces of synovium free as far as possible from underlying tissue, and as near as possible of uniform size (roughly 2x2 mm). These were washed in DMEM and cultured in the same medium buffered for 5°/0 CO, with bicarbonate for 48 hours at 370C in a 5% CO, incubator, changing the medium after 24 h. Four to six replicate cultures were set up from each patient's synovium.
The resulting media from the 24 h and 48 h cultures were assayed for CDA by a modification of the assay procedure of Dingle et a13 using smaller (2 5 mm) discs of bovine nasal cartilage and culturing in one uninterrupted period of six days. Dead cartilage was used as a control; no significant enzyme activity was found in the culture medium. The results were converted by the Logit transformation of the data obtained from a porcine catabolin standard dose-response curve into equivalent concentrations of a porcine synovial catabolin standard preparation, as described by Dingle and Qi" (1 !Al is equivalent to 0.2 ng pure porcine leucocyte IL1). The same media were also assayed for glucose to allow an estimation of the overall metabolic rate of the synovial tissue.
The synovial samples were freeze dried and weighed before being digested with papain and analysed for DNA.'2 Small pieces were removed before culture and examined histologically after staining with haematoxylin and eosin.
Results
The metabolic activity and cellularity of the rheumatoid and non-rheumatoid synovia populations are shown in Table 2 . There was only sufficient tissue for 14 of the 40 non-rheumatoid (traumatic) synovia to be assayed for DNA and glucose utilisation, but all tissue samples from 24 rheumatoid patients examined for CDA were so assayed. It is apparent that the cellularity (as measured by DNA/mg dry wt) of the rheumatoid synovium is some threefold greater than that of the non-rheumatoid tissue and that the glucose utilisation is about fourfold higher. Measurement of the CDA production by rheumatoid and non-rheumatoid tissues is shown in Table 3 . Fig. 1 , and similar comparisons between metabolic activity (glucose utilisation) and CDA production are shown in Fig. 2 . As can be seen from Fig. 1 most of the non-rheumatoid population had a CDA of <1 gl std/mg dry wt; most of these tissues had a low cellularity (<1-5 ,ug DNA/mg dry wt). In the few tissues with a higher cellularity there was no associated increase in CDA.
The rheumatoid patients examined appeared to consist of two distinct populations. In somewhat over half the samples tested the CDA activity was between 1l5 and 2-5 p1 std/mg dry wt and this was not related to the cellularity of the ti-ue, which ranged from 1 to 8 5 ,ig DNA/mg dry wt. In eight rheumatoid patients, however, the CDA was be- had a high cellularity (>4 tAg DNA/mg dry wt). The difference between these two populations was statistically significant (p<0-01). There would appear to be a number of patients whose synovial tissue was highly cellular and produced significantly higher levels of CDA than was present either in patients with relatively inactive rheumatoid arthritis or in the non-rheumatoid population. It was thought worthwhile determining whether the increased CDA was related to an increased metabolic activity of the tissues. There was no significant correlation, however, either in the nonrheumatoid or in the rheumatoid population between the metabolic activity (expressed as glucose utilised/mg dry wt) and the CDA of the synovial tissue (Fig. 2) .
In addition to the above results three osteoarthritic patients were examined; their CDA production was not appreciably different from that of normal (traumatic) synovia. Three intensely proliferative synovia of non-rheumatoid aetiology were also examined. In these cases there was a high production of .'DA (7-95 gl std/mg dry wt).
It has been known for some time that in vitro treatment of porcine synovial tissue with steroids depresses CDA production. '4 We have found that in vitro treatment of rheumatoid arthritic synovia (n= 12) with prednisolone (0-25 Ftg/ml) gave 62-68% inhibition of CDA production.
Discussion
The problem of assessing the biological activity of a tissue that is extremely heterogeneous in cell type and activity is very difficult. could argue that the total production of CDA in the rheumatoid joint is therefore much greater than in the normal. This is probably less important than local changes in CDA that may occur.
In this study there are two populations of RA tissues-those in which CDA is not directly related to cell number and others where there is clearly an increased CDA and an increased cellularity of the tissue. This active cell population may represent a local stimulation of CDA production by other cytokines. It would be particularly interesting to study the CDA production in the area of the cartilage/pannus junction, but this was not possible in the present work. Future studies using specific anti-ILl antisera will allow immunofluorescent localisation of this cytokine and will be of value in determining the cellular pattern of activation.
The well reported inhibition of CDA production in animal synovial tissue treated with seroids in vitro has been shown to occur in experiments with human synovial membrane in vitro. Such inhibition may occur in vivo. The use of steroids to suppress CDA production in vivo has not been explored to any great extent. If we can judge by in vitro work very low levels of these agents can suppress CDA production-a fact which may be of importance in preserving the integrity of articular cartilage.
Although the work reported in this paper concentrated on the catabolic effects of the human synovial tissue CDA, it must not be forgotten that recent work has shown that this catabolin/IL1 can also inhibit the synthesis of matrix components. '8 19 The combined effect, i.e., the inhibition of repair processes combined with an increased catabolic activity, shows that the synovial production of this cytokine could be important in controlling the development of the degenerative lesions in arthritic disease. 
